Ozempic for Weight Loss: Options, Clinical Criteria & Alternat...

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Direct access to semaglutide (Ozempic) for weight loss requires meeting specific clinical criteria: BMI ≥30 kg/m² or ≥27 with weight-related comorbidities, plus a prescription from a licensed provider. However, many patients explore compounded alternatives due to cost, availability, or provider preference—a choice that warrants careful clinical consideration.

Weight loss medication decisions involve more than brand name or price. Understanding your metabolic profile, genetic predispositions in GLP-1 pathways, and provider assessment can help you evaluate whether branded drugs, compounded formulations, or combination protocols best fit your clinical needs and treatment goals.

FDA Approval Status and Clinical Indications for Semaglutide Weight Loss

Semaglutide (Ozempic) received FDA approval for chronic weight management as Wegovy in 2021 for adults with BMI ≥30 or BMI ≥27 with weight-related conditions like hypertension or type 2 diabetes. The approval was based on clinical trials showing 15% mean body weight reduction over 68 weeks versus placebo.

Ozempic itself carries a diabetes indication only; Wegovy is the FDA-cleared brand for weight loss. This distinction matters for insurance coverage, prescription routing, and whether a provider can legally prescribe off-label. Understanding this regulatory landscape helps patients and providers navigate legitimate pathways to GLP-1 therapy.

Eligibility Criteria and Provider Assessment Requirements

To qualify for semaglutide or tirzepatide weight loss therapy, providers typically assess BMI, baseline weight, comorbidities, cardiovascular risk, kidney function, and contraindications (history of medullary thyroid cancer, pancreatitis, or personal/family history of multiple endocrine neoplasia). A thorough metabolic and medical history is essential before initiating therapy.

Evaluation frameworks vary by provider and practice setting. Some emphasize metabolic biomarkers (fasting glucose, insulin, lipids), others focus on symptom severity or previous weight loss attempts. This individualized assessment is key to determining whether GLP-1 therapy is clinically appropriate and safe for your specific health profile.

Eligibility Factor	Typical Clinical Threshold
BMI (without comorbidities)	≥30 kg/m²
BMI (with weight-related disease)	≥27 kg/m² + hypertension, T2D, sleep apnea, or cardiovascular disease
Kidney function	eGFR >15 mL/min/1.73m² (varies by agent)
Contraindications to screen	Personal/family hx medullary thyroid cancer, MEN2, acute pancreatitis, or severe GI disease
Cardiovascular risk assessment	Baseline BP, lipids, ECG (depending on age and comorbidities)

Cost, Access, and Why Patients Consider Compounded Alternatives

Branded semaglutide (Wegovy) costs $900–$1,400/month without insurance; Ozempic for weight loss can exceed $1,300/month. Many commercial and Medicare plans require step therapy, prior authorization, or don't cover weight loss indications. Compounded semaglutide from licensed 503A pharmacies costs $179–$229/month, creating significant cost barriers that drive patients to explore alternatives.

Compounded GLP-1 formulations offer lower cost and flexible dosing but lack FDA approval, long-term safety data equivalent to branded drugs, and standardized manufacturing oversight. Any decision to use compounded agents should involve discussion with a qualified provider about bioavailability, consistency, and individual safety considerations.

Safety Considerations, Contraindications, and Medical Supervision

Common GLP-1 side effects include nausea, vomiting, diarrhea, and abdominal pain—often dose-dependent and transient. Serious but rare risks include pancreatitis, gallbladder disease, and dehydration. Patients with kidney disease, dehydration risk, or personal/family history of medullary thyroid cancer or MEN2 require extra caution and may not be candidates.

Regardless of whether you choose branded or compounded formulations, ongoing provider monitoring—including weight, metabolic markers, symptoms, and adherence—is essential. Compounded medications especially require regular clinical contact to assess efficacy, side effects, and whether dosing adjustments or alternative approaches are needed.

How Genetic Insights into GLP-1 Pathways Can Inform Your Choice

Your genetic makeup influences how your body responds to GLP-1 receptor agonists. Variants in GLP1R, GIPR, FTO, and MC4R genes may predispose you to stronger or weaker appetite suppression, weight loss trajectory, or medication side effects. Understanding these predispositions can help guide more personalized treatment selection.

PlexusDx's Precision Peptide Genetic Test examines key variants in peptide metabolism pathways—not to predict exact medication response, but to reveal genetic predispositions that may support a more informed conversation with your provider. This context, combined with your clinical profile and goals, can help determine whether branded, compounded, or combination GLP-1 approaches align with your physiology and needs.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that GLP-1 therapy—whether branded or compounded—is not one-size-fits-all. Genetic predispositions in peptide signaling pathways, combined with your clinical biomarkers and metabolic history, may help provide context for why certain formulations or dosing strategies work better for some patients. This precision-wellness approach supports more personalized decision-making with your provider.

The Precision Peptide Genetic Test (standalone $298 or $99 add-on) reveals predispositions across GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—markers linked to appetite regulation, weight loss response, and metabolic traits. These results should be interpreted with a qualified healthcare provider to contextualize your individual biology within the larger clinical picture.

Combining genetic insights with clinical assessment can support a more informed conversation about GLP-1 eligibility, which formulation (branded or compounded) may align with your response patterns, and how to monitor progress. PlexusDx's role is to provide this genetic context and access to cost-effective compounded options—not to replace clinical evaluation, but to enhance it.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.